Antimalarial drugs inhibit IFNα-enhanced TNFα and STAT4 expression in monocytes: Implication for systemic lupus erythematosus

Cytokine

Volumn 67, Issue 1, 2014, Pages 13-20

  López, Patricia ^a   Rodríguez Carrio, Javier ^a   Suárez, Ana ^a  

^a UNIVERSITY OF OVIEDO   (Spain)

Author keywords

Antimalarial therapy; IFN ; STAT4; Systemic lupus erythematosus; TNF

Indexed keywords

ALPHA INTERFERON; ANTIMALARIAL AGENT; CHLOROQUINE; REGULATOR PROTEIN; STAT4 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; STAT4 PROTEIN, HUMAN;

ADULT; ANTIMALARIAL ACTIVITY; ARTICLE; CELL CULTURE; CELL POPULATION; CELL STIMULATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MONOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN INTERACTION; PROTEIN MODIFICATION; PROTEIN SYNTHESIS INHIBITION; QUANTITATIVE ANALYSIS; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; UPREGULATION; ADOLESCENT; BIOSYNTHESIS; BLOOD; IMMUNOLOGY; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; MONONUCLEAR CELL; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIMALARIALS; CELLS, CULTURED; CHLOROQUINE; FEMALE; HUMANS; INTERFERON-ALPHA; LEUKOCYTES, MONONUCLEAR; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; STAT4 TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION; YOUNG ADULT;

EID: 84894592575     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2014.02.002     Document Type: Article

References (56)

1. Blanco P., Palucka A.K., Gill M., Pascual V., Banchereau J. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science 2001, 294:1540-1543.
2. López P., Gutiérrez C., Suárez A. IFNalpha treatment generates antigen-presenting cells insensitive to atorvastatin inhibition of MHC-II expression. Clin Immunol 2008, 129(2):350-359.
3. Jego G., Palucka A.K., Blanck J.-P., Chalouni C., Pascual V., Banchereau J. Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity 2003, 19(2):225-234.
4. Rönnblom L. The type I interferon system in the etiopathogenesis of autoimmune diseases. Ups J Med Sci 2011, 116(4):227-237.
5. Baechler E.C., Batliwalla F.M., Karypis G., Gaffney P.M., Ortmann W.A., Espe K.J., et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA 2003, 100(5):2610-2615.
6. Crow M.K., Wohlgemuth J. Microarray analysis of gene expression in lupus. Arthritis Res Ther 2003, 5(6):279-287.
7. Rönnblom L., Alm G.V. An etiopathogenic role for the type I IFN system in SLE. Trends Immunol 2001, 22(8):427-431.
8. Barrat F.J., Meeker T., Gregorio J., Chan J.H., Uematsu S., Akira S., et al. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J Exp Med 2005, 202(8):1131-1139.
9. Means T.K., Latz E., Hayashi F., Murali M.R., Golenbock D.T., Luster A.D. Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. J Clin Invest 2005, 115(2):407-417.
10. Tyler D.R., Persky M.E., Matthews L.A., Chan S., Farrar J.D. Pre-assembly of STAT4 with the human IFN-alpha/beta receptor-2 subunit is mediated by the STAT4 N-domain. Mol Immunol 2007, 44(8):1864-1872.
11. Thieu V.T., Yu Q., Chang H.-C., Yeh N., Nguyen E.T., Sehra S., et al. Signal transducer and activator of transcription 4 is required for the transcription factor T-bet to promote T helper 1 cell-fate determination. Immunity 2008, 29(5):679-690.
12. Remmers E.F., Plenge R.M., Lee A.T., Graham R.R., Hom G., Behrens T.W., et al. STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N Engl J Med 2007, 357(10):977-986.
13. Sigurdsson S., Nordmark G., Garnier S., Grundberg E., Kwan T., Nilsson O., et al. A risk haplotype of STAT4 for systemic lupus erythematosus is over-expressed, correlates with anti-dsDNA and shows additive effects with two risk alleles of IRF5. Hum Mol Genet 2008, 17(18):2868-2876.
14. Taylor K.E., Remmers E.F., Lee A.T., Ortmann W.A., Plenge R.M., Tian C., et al. Specificity of the STAT4 genetic association for severe disease manifestations of systemic lupus erythematosus. PLoS Genet 2008, 4(5):e1000084.
15. Costedoat-Chalumeau N., Amoura Z., Hulot J.-S., Hammoud H.A., Aymard G., Cacoub P., et al. Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. Arthritis Rheum 2006, 54(10):3284-3290.
16. Ruiz-Irastorza G., Ramos-Casals M., Brito-Zeron P., Khamashta M.A. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 2010, 69(01):20-28.
17. Zhu X., Ertel W., Ayala A., Morrison M.H., Perrin M.M., Chaudry I.H. Chloroquine inhibits macrophage tumour necrosis factor-alpha mRNA transcription. Immunology 1993, 80(1):122-126.
18. Weber S.M., Levitz S.M. Chloroquine interferes with lipopolysaccharide-induced TNF-alpha gene expression by a nonlysosomotropic mechanism. J Immunol 2000, 165(3):1534-1540.
19. Weber S.M., Chen J.-M., Levitz S.M. Inhibition of mitogen-activated protein kinase signaling by chloroquine. J Immunol 2002, 168(10):5303-5309.
20. López P., Gómez J., Mozo L., Gutiérrez C., Suárez A. Cytokine polymorphisms influence treatment outcomes in SLE patients treated with antimalarial drugs. Arthritis Res Ther 2006, 8(2):R42.
21. Wozniacka A., Lesiak A., Narbutt J., McCauliffe D.P., Sysa-Jedrzejowska A. Chloroquine treatment influences proinflammatory cytokine levels in systemic lupus erythematosus patients. Lupus 2006, 15(5):268-275.
22. Lafyatis R., York M., Marshak-Rothstein A. Antimalarial agents: closing the gate on Toll-like receptors?. Arthritis Rheum 2006, 54(10):3068-3070.
23. López P., Gómez J., Prado C., Gutiérrez C., Suárez A. Influence of functional interleukin 10/tumor necrosis factor-alpha polymorphisms on interferon-alpha, IL-10, and regulatory T cell population in patients with systemic lupus erythematosus receiving antimalarial treatment. J Rheumatol 2008, 35(8):1559-1566.
24. Weckerle C.E., Imbuka D., Franek B.S., Kelly J.A., Kumabe M., James J.A., et al. Large scale analysis of tumor necrosis factor alpha levels in systemic lupus erythematosus. Arthritis Rheum 2012, 64:2947-2952.
25. Aringer M., Feierl E., Steiner G., Stummvoll G.H., Höfler E., Steiner C.W., et al. Increased bioactive TNF in human systemic lupus erythematosus: associations with cell death. Lupus 2002, 11(2):102-108.
26. Seager Danciger J., Lutz M., Hama S., Cruz D., Castrillo A., Lazaro J., et al. Method for large scale isolation, culture and cryopreservation of human monocytes suitable for chemotaxis, cellular adhesion assays, macrophage and dendritic cell differentiation. J Immunol Methods 2004, 288(1-2):123-134.
27. Gómez J., Suárez A., López P., Mozo L., Díaz J.B., Gutiérrez C. Systemic lupus erythematosus in Asturias, Spain: clinical and serologic features. Medicine (Baltimore) 2006, 85(3):157-168.
28. López P., Mozo L., Gutiérrez C., Suárez A. Epidemiology of systemic lupus erythematosus in a northern Spanish population: gender and age influence on immunological features. Lupus 2003, 12(11):860-865.
29. Tan E.M., Cohen A.S., Fries J.F., Masi A.T., McShane D.J., Rothfield N.F., et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982, 25(11):1271-1277.
30. Coclet-Ninin J., Dayer J.M., Burger D. Interferon-beta not only inhibits interleukin-1beta and tumor necrosis factor-alpha but stimulates interleukin-1 receptor antagonist production in human peripheral blood mononuclear cells. Eur Cytokine Network 1997, 8(4):345-349.
31. Jungo F., Dayer J.M., Modoux C., Hyka N., Burger D. IFN-beta inhibits the ability of T lymphocytes to induce TNF-alpha and IL-1beta production in monocytes upon direct cell-cell contact. Cytokine 2001, 14(5):272-282.
32. Uitdehaag B.M., Hoekstra K., Koper J.W., Polman C.H., Dijkstra C.D. IFN-beta1b augments glucocorticoid-induced suppression of tumor necrosis factor-alpha production by increasing the number of glucocorticoid receptors on a human monocytic cell line. J Interferon Cytokine Res 2001, 21(3):133-135.
33. Sauer I., Schaljo B., Vogl C., Gattermeier I., Kolbe T., Müller M., et al. Interferons limit inflammatory responses by induction of tristetraprolin. Blood 2006, 107(12):4790-4797.
34. Sharif M.N., Sosic D., Rothlin C.V., Kelly E., Lemke G., Olson E.N., et al. Twist mediates suppression of inflammation by type I IFNs and Axl. J Exp Med 2006, 203(8):1891-1901.
35. Molnarfi N., Gruaz L., Dayer J.-M., Burger D. Opposite effects of IFN beta on cytokine homeostasis in LPS- and T cell contact-activated human monocytes. J Neuroimmunol 2004, 146(1-2):76-83.
36. Taniguchi T., Takaoka A. A weak signal for strong responses: interferon-alpha/beta revisited. Nat Rev Mol Cell Biol 2001, 2(5):378-386.
37. Niewold T.B., Kariuki S.N., Morgan G.A., Shrestha S., Pachman L.M. Elevated serum interferon alpha activity in juvenile dermatomyositis: associations with disease activity at diagnosis and after 36months of therapy. Arthritis Rheum 2009, 60(6):1815-1824.
38. Yao Y., Richman L., Higgs B.W., Morehouse C.A., De los Reyes M., Brohawn P., et al. Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum 2009, 60(6):1785-1796.
39. Cantaert T., Baeten D., Tak P.P., Van Baarsen L.G. Type I IFN and TNFα cross-regulation in immune-mediated inflammatory disease: basic concepts and clinical relevance. Arthritis Res Ther 2010, 12(5):219.
40. Bennett L., Palucka A.K., Arce E., Cantrell V., Borvak J., Banchereau J., et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003, 197(6):711-723.
41. Studnicka-Benke A., Steiner G., Petera P., Smolen J.S. Tumour necrosis factor alpha and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus. Br J Rheumatol 1996, 35(11):1067-1074.
42. Rönnblom L., Alm G.V. A pivotal role for the natural interferon alpha-producing cells (plasmacytoid dendritic cells) in the pathogenesis of lupus. J Exp Med 2001, 194(12):F59-F63.
43. Hoshino K., Sugiyama T., Matsumoto M., Tanaka T., Saito M., Hemmi H., et al. IkappaB kinase-alpha is critical for interferon-alpha production induced by Toll-like receptors 7 and 9. Nature 2006, 440(7086):949-953.
44. Abrahams V.M., Cambridge G., Lydyard P.M., Edwards J.C. Induction of tumor necrosis factor alpha production by adhered human monocytes: a key role for Fcgamma receptor type IIIa in rheumatoid arthritis. Arthritis Rheum 2000, 43(3):608-616.
45. Yarilina A., Park-Min K.-H., Antoniv T., Hu X., Ivashkiv L.B. TNF activates an IRF1-dependent autocrine loop leading to sustained expression of chemokines and STAT1-dependent type I interferon-response genes. Nat Immunol 2008, 9(4):378-387.
46. The Canadian Hydroxychloroquine Study Group A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med 1991, 324(3):150-154.
47. Lövgren T., Eloranta M.-L., Kastner B., Wahren-Herlenius M., Alm G.V., Rönnblom L. Induction of interferon-alpha by immune complexes or liposomes containing systemic lupus erythematosus autoantigen- and Sjögren's syndrome autoantigen-associated RNA. Arthritis Rheum 2006, 54(6):1917-1927.
48. Kwok S.-K., Lee J.-Y., Park S.-H., Cho M.-L., Min S.-Y., Park S.-H., et al. Dysfunctional interferon-α production by peripheral plasmacytoid dendritic cells upon Toll-like receptor-9 stimulation in patients with systemic lupus erythematosus. Arthritis Res Ther 2008, 10(2):R29.
49. Martinson J.A., Montoya C.J., Usuga X., Ronquillo R., Landay A.L., Desai S.N. Chloroquine modulates HIV-1-induced plasmacytoid dendritic cell alpha interferon: implication for T-cell activation. Antimicrob Agents Chemother 2010, 54(2):871-881.
50. Willis R., Seif A.M., McGwin G., Martinez-Martinez L.A., González E.B., Dang N., et al. Effect of hydroxychloroquine treatment on pro-inflammatory cytokines and disease activity in SLE patients: data from LUMINA (LXXV), a multiethnic US cohort. Lupus 2012, 21(8):830-835.
51. Sacre K., Criswell L.A., McCune J.M. Hydroxychloroquine is associated with impaired interferon-alpha and tumor necrosis factor-alpha production by plasmacytoid dendritic cells in systemic lupus erythematosus. Arthritis Res Ther 2012, 14(3):R155.
52. Frucht D.M., Aringer M., Galon J., Danning C., Brown M., Fan S., et al. Stat4 is expressed in activated peripheral blood monocytes, dendritic cells, and macrophages at sites of Th1-mediated inflammation. J Immunol 2000, 164(9):4659-4664.
53. Kariuki S.N., Kirou K.A., MacDermott E.J., Barillas-Arias L., Crow M.K., Niewold T.B. Cutting edge: autoimmune disease risk variant of STAT4 confers increased sensitivity to IFN-α in lupus patients in vivo. J Immunol 2009, 182:34-38.
54. Kawai T., Akira S. TLR signaling. Semin Immunol 2007, 19(1):24-32.
55. Abelson A.-K., Delgado-Vega A.M., Kozyrev S.V., Sánchez E., Velázquez-Cruz R., Eriksson N., et al. STAT4 associates with systemic lupus erythematosus through two independent effects that correlate with gene expression and act additively with IRF5 to increase risk. Ann Rheum Dis 2009, 68(11):1746-1753.
56. Weckerle C.E., Franek B.S., Kelly J.A., Kumabe M., Mikolaitis R.A., Green S.L., et al. Network analysis of associations between serum interferon-α activity, autoantibodies, and clinical features in systemic lupus erythematosus. Arthritis Rheum 2011, 63(4):1044-1053.